FR13C0044I2 - Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine - Google Patents

Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Info

Publication number: FR13C0044I2
Authority: FR; France
Prior art keywords: dihydroimidazolones; treatment; canine epilepsy; canine; epilepsy
Prior art date: 2002-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR13C0044C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Boehringer Ingelheim Vetmedica GmbH

Original Assignee

Boehringer Ingelheim Vetmedica GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-10

Filing date

2013-07-24

Publication date

2014-03-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32094042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0044(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-24 Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH

2013-08-30 Publication of FR13C0044I1 publication Critical patent/FR13C0044I1/fr

2014-03-07 Application granted granted Critical

2014-03-07 Publication of FR13C0044I2 publication Critical patent/FR13C0044I2/fr

Status Active legal-status Critical Current

Links

206010015037 epilepsy Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR13C0044C 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine Active FR13C0044I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41759002P	2002-10-10	2002-10-10
PCT/EP2003/011212 WO2004032938A1 (fr)	2002-10-10	2003-10-09	Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Publications (2)

Publication Number	Publication Date
FR13C0044I1 FR13C0044I1 (fr)	2013-08-30
FR13C0044I2 true FR13C0044I2 (fr)	2014-03-07

Family

ID=32094042

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR13C0044C Active FR13C0044I2 (fr)	2002-10-10	2013-07-24	Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR22C1033C Active FR22C1033I1 (fr)	2002-10-10	2022-06-30	Utilisation de dihydroimidazolones pour le traitement des chiens

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR22C1033C Active FR22C1033I1 (fr)	2002-10-10	2022-06-30	Utilisation de dihydroimidazolones pour le traitement des chiens

Country Status (27)

Country	Link
US (5)	US20050070537A1 (fr)
EP (3)	EP2036563A1 (fr)
JP (4)	JP4694202B2 (fr)
KR (2)	KR101110587B1 (fr)
CN (2)	CN1726040B (fr)
AR (1)	AR041573A1 (fr)
AT (1)	ATE418337T1 (fr)
AU (2)	AU2003273978B2 (fr)
BE (1)	BE2013C046I2 (fr)
BR (1)	BR0315225A (fr)
CA (2)	CA2501772C (fr)
CY (3)	CY1109961T1 (fr)
DE (1)	DE60325496D1 (fr)
DK (2)	DK1553952T3 (fr)
ES (2)	ES2908453T3 (fr)
FR (2)	FR13C0044I2 (fr)
HR (3)	HRP20090667B1 (fr)
HU (2)	HUS1300035I1 (fr)
LU (1)	LU92238I2 (fr)
MX (1)	MXPA05003663A (fr)
NZ (1)	NZ539864A (fr)
PL (2)	PL238776B1 (fr)
PT (2)	PT1553952E (fr)
SI (2)	SI1553952T1 (fr)
TW (2)	TWI324067B (fr)
WO (1)	WO2004032938A1 (fr)
ZA (1)	ZA200502245B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
JP2009513539A (ja) *	2003-07-11	2009-04-02	ベーリンガー・インゲルハイム・フエトメデイカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング	ベンゾジアゼピンレセプターのアルファ３サブユニットに対する選択性を有する化合物を用いて中枢神経系障害を治療または予防する方法
AR089646A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
JP6193613B2 (ja) *	2013-05-10	2017-09-06	学校法人麻布獣医学園	てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
WO2015182724A1 (fr)	2014-05-28	2015-12-03	トーアエイヨー株式会社	Dérivés de tropane substitués
WO2016044370A1 (fr)	2014-09-16	2016-03-24	India Globalization Capital, Inc.	Composition cannabinoïde et méthode de traitement de la douleur
WO2016118391A1 (fr)	2015-01-25	2016-07-28	India Globalization Capital, Inc.	Compositions et procédés de traitement de troubles épileptiques
US10596159B2 (en)	2015-08-12	2020-03-24	India Globalization Capital, Inc.	Method and composition for treating cachexia and eating disorders
WO2017218629A1 (fr)	2016-06-15	2017-12-21	India Globalization Capital, Inc.	Méthode et composition pour traiter des troubles epileptiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4044021A (en)	1971-10-21	1977-08-23	American Cyanamid Company	Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en)	1975-02-07	1976-01-13	Morton-Norwich Products, Inc.	1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de)	1995-09-05	1997-03-06	Dresden Arzneimittel	Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en)	1995-09-05	1999-02-09	Arzneitmittelwerk Dresden G.M.B.H.	Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) *	1997-05-23	1998-11-26	Dresden Arzneimittel	Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
EP0991614A1 (fr) *	1997-06-26	2000-04-12	Board of Regents, The University of Texas System	Synthese de compositions de dihydrohonokiol
JP4669095B2 (ja)	1999-07-19	2011-04-13	太陽化学株式会社	ペットの問題行動抑制組成物
SI1870100T1 (sl)	2002-03-07	2012-05-31	Boehringer Ingelheim Int	Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de)	2003-08-29	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AR089646A1 (es)	2011-08-12	2014-09-10	Boehringer Ingelheim Vetmed	Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals

2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW092127976A patent/TWI324067B/zh not_active IP Right Cessation
- 2003-10-08 TW TW098142077A patent/TWI424849B/zh not_active IP Right Cessation
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/hr not_active IP Right Cessation
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/zh not_active Expired - Lifetime
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/fr not_active Ceased
- 2003-10-09 AR ARP030103685A patent/AR041573A1/es unknown
- 2003-10-09 EP EP08167818A patent/EP2036563A1/fr not_active Ceased
- 2003-10-09 AT AT03757945T patent/ATE418337T1/de active
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/ko not_active Expired - Lifetime
- 2003-10-09 DK DK03757945T patent/DK1553952T3/da active
- 2003-10-09 PL PL397320A patent/PL238776B1/pl unknown
- 2003-10-09 SI SI200331504T patent/SI1553952T1/sl unknown
- 2003-10-09 EP EP03757945A patent/EP1553952B1/fr not_active Expired - Lifetime
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/es active IP Right Grant
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/fr not_active Expired - Lifetime
- 2003-10-09 PT PT03757945T patent/PT1553952E/pt unknown
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/ko not_active Ceased
- 2003-10-09 PL PL374603A patent/PL214702B1/pl unknown
- 2003-10-09 DE DE60325496T patent/DE60325496D1/de not_active Expired - Lifetime
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/ja not_active Expired - Lifetime
- 2003-10-09 HR HRP20050322AA patent/HRP20050322B1/hr not_active IP Right Cessation
- 2003-10-09 ES ES14191084T patent/ES2908453T3/es not_active Expired - Lifetime
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/zh active Pending
- 2003-10-09 SI SI200332622T patent/SI2845594T1/sl unknown
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/pt not_active Application Discontinuation
- 2003-10-09 CA CA2501772A patent/CA2501772C/fr not_active Expired - Lifetime
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/da active
- 2003-10-09 CA CA2727722A patent/CA2727722C/fr not_active Expired - Lifetime
- 2003-10-09 ES ES03757945T patent/ES2316808T3/es not_active Expired - Lifetime
- 2003-10-09 PT PT141910844T patent/PT2845594T/pt unknown
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
- 2003-10-09 HR HRP20200207AA patent/HRP20200207A2/hr not_active Application Discontinuation
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en not_active Expired - Lifetime
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/el unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/ja not_active Withdrawn
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
2013
- 2013-07-03 LU LU92238C patent/LU92238I2/fr unknown
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I2/el unknown
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/hu unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/fr active Active
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/ja not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Fee Related
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/ja not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/el unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/fr active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/hu unknown

Also Published As

Publication number	Publication date
EP2036563A1 (fr)	2009-03-18
FR22C1033I1 (fr)	2022-09-09
WO2004032938A1 (fr)	2004-04-22
LU92238I9 (fr)	2019-01-09
PT1553952E (pt)	2009-02-10
KR101110587B1 (ko)	2012-02-15
MXPA05003663A (es)	2005-06-08
KR20110063843A (ko)	2011-06-14
JP2011068685A (ja)	2011-04-07
FR13C0044I1 (fr)	2013-08-30
AU2009225322A1 (en)	2009-11-05
US20080027057A1 (en)	2008-01-31
US20130065898A1 (en)	2013-03-14
US8962617B2 (en)	2015-02-24
US9469611B2 (en)	2016-10-18
DE60325496D1 (de)	2009-02-05
EP2845594B1 (fr)	2022-02-23
NZ539864A (en)	2007-11-30
US20150072983A1 (en)	2015-03-12
US20050070537A1 (en)	2005-03-31
CY1125103T1 (el)	2023-01-05
AU2003273978B2 (en)	2009-07-23
JP2016104817A (ja)	2016-06-09
DK2845594T3 (da)	2022-03-07
TW200503726A (en)	2005-02-01
BE2013C046I2 (fr)	2022-08-09
CA2501772A1 (fr)	2004-04-22
PL238776B1 (pl)	2021-10-04
KR20050056237A (ko)	2005-06-14
US20160367562A1 (en)	2016-12-22
LU92238I2 (fr)	2013-09-03
CA2501772C (fr)	2011-08-23
BR0315225A (pt)	2005-08-23
HRP20090667A2 (hr)	2010-07-31
EP1553952B1 (fr)	2008-12-24
CN1726040A (zh)	2006-01-25
PL397320A1 (pl)	2012-02-13
ES2316808T3 (es)	2009-04-16
DK1553952T3 (da)	2009-04-20
JP6249812B2 (ja)	2017-12-20
HRP20090667B1 (hr)	2021-06-11
EP2845594A1 (fr)	2015-03-11
SI2845594T1 (sl)	2022-04-29
PL374603A1 (en)	2005-10-31
AU2003273978A1 (en)	2004-05-04
CA2727722C (fr)	2013-05-28
HUS2200036I1 (hu)	2022-08-28
HK1085920A1 (zh)	2006-09-08
JP2006503873A (ja)	2006-02-02
US8859540B2 (en)	2014-10-14
PL214702B1 (pl)	2013-09-30
PT2845594T (pt)	2022-03-09
CA2727722A1 (fr)	2004-04-22
ATE418337T1 (de)	2009-01-15
CY2013031I1 (el)	2015-11-04
CY2013031I2 (el)	2015-11-04
JP2014080449A (ja)	2014-05-08
EP1553952A1 (fr)	2005-07-20
AR041573A1 (es)	2005-05-18
TWI424849B (zh)	2014-02-01
HRP20050322A2 (en)	2006-05-31
HUS1300035I1 (hu)	2017-10-30
ES2908453T3 (es)	2022-04-29
HRP20050322B1 (hr)	2013-12-06
CN101890019A (zh)	2010-11-24
HRP20200207A2 (hr)	2020-07-24
JP4694202B2 (ja)	2011-06-08
SI1553952T1 (sl)	2009-04-30
CY1109961T1 (el)	2014-09-10
TW201010706A (en)	2010-03-16
ZA200502245B (en)	2005-11-30
CN1726040B (zh)	2010-05-12
TWI324067B (en)	2010-05-01

Publication	Publication Date	Title
EP1534074A4 (fr)	2008-01-09	Polytherapie pour le traitement de l'obesite
FR22C1033I1 (fr)	2022-09-09	Utilisation de dihydroimidazolones pour le traitement des chiens
FR2854074B1 (fr)	2007-11-23	Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP1501489A4 (fr)	2007-11-21	Polytherapie pour le traitement de cancer
FR13C0029I2 (fr)	2024-04-19	Compositions pour le traitement de troubles gastro-intestinaux
EP1587502A4 (fr)	2011-05-25	Pansement pour blessure
CH1143977H1 (fr)	2007-02-15	2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR2846870B1 (fr)	2005-07-01	Materiel d'osteosynthese pour le traitement d'un cubitus"long"
EP1601251A4 (fr)	2007-03-28	Compos s pour le traitement de troubles m taboliques
FR13C0060I2 (fr)	2014-04-11	Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP1601329A4 (fr)	2010-08-25	Systeme automatise de traitement de l'insomnie
EP1641748A4 (fr)	2006-11-22	Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
EP1551369A4 (fr)	2007-05-09	Therapie de combinaison pour le traitement de troubles fibrosants
EP1727530A4 (fr)	2009-10-21	Formulations topiques pour le traitement d'etats dermatologiques
DZ3014A1 (fr)	2004-03-27	Médicaments pour le traitement de l'hypertension.
EP1581243A4 (fr)	2008-01-02	Lactoferrine orale pour le traitement des sepsies
EP1750513A4 (fr)	2009-07-22	Utilisation de ligands gpcr54 pour le traitement de l'infertilite
EP1448193A4 (fr)	2005-11-23	Composes therapeutiques pour le traitement d'etats dyslipidemiques
FR2835851B1 (fr)	2004-04-23	Composition pour le traitement d'alliages de magnesium
EP1558238A4 (fr)	2006-08-30	Beta-hydroxyphenylaldylamines et utilisation de celles-ci pour traiter le glaucome
EP1572129A4 (fr)	2007-03-28	Derives d'amidine pour le traitement des amyloses
FR2800614B1 (fr)	2002-01-04	Composition pour le traitement des infections des voies respiratoires
MA25852A1 (fr)	2003-07-01	Methode pour le traitement de l'inflammation.
EP1687275A4 (fr)	2009-01-14	Composes de pyridin-4-ylamine convenant pour le traitement de la douleur neuropathique
DE60005685D1 (de)	2003-11-06	Oxazinocarbazole zur behandlung von cns-erkrankungen